Form 8-K Alector, Inc. For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
GSK terminates collaboration with Alector after trial failures
July 8, 2026 4:13 PM EDTAlector Inc. (NASDAQ: ALEC) disclosed that GlaxoSmithKline unit Glaxo Wellcome UK Limited has moved to terminate its collaboration and license agreement with the company, following the failure of two clinical trials.
GSK provided written notice of termination on July 6, 2026. Under the agreement's terms, the... More



